Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.
Also called NCT01691313
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 104 participants
- Sponsor
- Laguna Pharmaceuticals, Inc.
- Registry
-
NCT01691313
-
- Other papers using this trial's data
- COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Israel, Russia
- Registry status
- Completed
Technical summary
Registry record NCT01691313. Randomized; quadruple masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
- Acronym
- COR-ART
- Condition
- Symptomatic Atrial Fibrillation
- Condition
- Atrial Flutter
- Intervention (Drug)
- Vanoxerine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Laguna Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct01691313- Content hash
0757320426091e38eac879e5d2009a208c980040ef7b38b70fe162701cbef8e2